Expression of Endothelin-1 in the Lungs of Patients with Pulmonary Hypertension

Giaid, Adel; Yanagisawa, Masashi; Langleben, David; Michel, René P.; Levy, Robert D.; Shennib, Hani; Kimura, Sadao; Masaki, Τοmoh; Duguid, W. P.; Stewart, Duncan J.

doi:10.1056/nejm199306173282402

Cited by 1,686 publications

(955 citation statements)

References 30 publications

Supporting

Mentioning

896

Contrasting

Unclassified

Order By: Relevance

“…VEGF [22], endothelin-1 [32], and survivin [33;34] are among the factors present in plexiform lesions that may enhance endothelial cell and smooth muscle cell proliferation or decrease vascular cell apoptosis. These lesions have decreased expression of anti-remodeling mediators such as nitric oxide synthase [35] and prostacyclin synthase [36], and tumor suppressors, such as caveolin-1 [37].…”

Section: Pathobiologymentioning

confidence: 99%

Pathology of Pulmonary Hypertension

Tuder

Marecki

Richter

et al. 2013

Clinics in Chest Medicine

220

107

View full text Add to dashboard Cite

Section: Pathobiologymentioning

confidence: 99%

Pathology of Pulmonary Hypertension

Tuder

Marecki

Richter

et al. 2013

Clinics in Chest Medicine

220

107

View full text Add to dashboard Cite

“…ET levels are elevated in the plasma of patients with PH [42][43][44][45] and there is increased expression of ET-1 protein and mRNA in the endothelial cells of affected vessels in patients with PH [46]. In 21 patients with IPAH, elevated ET-1 levels correlated with right atrial pressure and pulmonary artery oxygen saturation [37].…”

Section: Natriuretic Peptidesmentioning

confidence: 99%

Biomarkers in pulmonary hypertension

Warwick

Thomas²,

Yates³

2008

Eur Respir J

140

View full text Add to dashboard Cite

There have been significant recent advances in the understanding of the pathophysiology of pulmonary hypertension, and a growing number of therapeutic agents have become available to the treating physician. Traditional methods of diagnosing and monitoring this condition have comprised echocardiography and right heart catheterisation, in addition to functional measures, such as estimation of functional class and the 6-min walk test. An increasing number of biomarkers have been described that are elevated in pulmonary hypertension and which may assist the clinician in diagnosis and in the assessment of disease severity and response to treatment.The present article details the more important biomarkers, their potential applications and the evidence supporting their use.

show abstract

“…Levels of endothelin-1 have been related to disease severity and survival. 54,55 The effects of endothelin-1 are mediated through two types of receptors ET A and ET B . ET A receptors cause sustained vasoconstriction and proliferation of vascular smooth muscles and ET B receptors induce production of NO and prostacyclin by the endothelial cells, thereby producing vasodilatation.…”

Section: Endothelin Receptor Antagonistsmentioning

confidence: 99%

Pulmonary hypertension—“state of the art” management in 2012

Saxena

2012

Indian Heart Journal

View full text Add to dashboard Cite

A B S T R A C TPulmonary artery hypertension (PAH) is a pathological condition of small pulmonary arteries, characterised by vascular proliferation and remodelling. The pulmonary artery pressure and pulmonary vascular resistance progressively rise, leading to right heart failure and death. Pulmonary artery hypertension may be secondary to various conditions, or it may be idiopathic where no underlying cause is identifiable. Earlier, only symptomatic treatment was available for such patients which did not change the natural history of the disease. However, over the years, improvement in understanding the pathogenesis has resulted in the development of targeted approaches to the treatment of PAH. Survival advantage has also been shown with some of the pharmacologic agents. This review article discusses the current management strategy for PAH with special emphasis on an idiopathic variety, in an Indian context.

show abstract

Expression of Endothelin-1 in the Lungs of Patients with Pulmonary Hypertension

Abstract: Pulmonary hypertension is associated with the increased expression of endothelin-1 in vascular endothelial cells, suggesting that the local production of endothelin-1 may contribute to the vascular abnormalities associated with this disorder.

Cited by 1,686 publications

References 30 publications

Pathology of Pulmonary Hypertension

Pathology of Pulmonary Hypertension

Biomarkers in pulmonary hypertension

Pulmonary hypertension—“state of the art” management in 2012

Contact Info

Product

Resources

About